Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
An announcement from Atrys Health SA ( (ES:ATRY) ) is now available.
Atrys Health SA reported a revenue increase of 5.5% in 2024, reaching 212.7 million euros, with a significant EBITDA growth of 13.8% to 48.5 million euros. The company reduced its negative consolidated result by 31% and improved its leverage ratio, reflecting the strength and efficiency of its business model. Atrys experienced growth across all business areas, particularly in oncology, driven by its activities in Mexico, and saw notable revenue increases in Spain, Portugal, and Latin America.
More about Atrys Health SA
Atrys is a global healthtech company specializing in prevention, diagnosis, and precision medical treatment services. It is a leader in telemedicine and oncology treatment, with operations in seven countries across Europe and Latin America, and is the only listed company in the health technology sector in Spain.
YTD Price Performance: -10.40%
Average Trading Volume: 245
Technical Sentiment Signal: Strong Buy
Current Market Cap: €234.8M
See more data about ATRY stock on TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue